



## Compass Therapeutics Announces Participation in March 2021 Investor Conferences

March 4, 2021

BOSTON--(BUSINESS WIRE)-- Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer of Compass Therapeutics, will participate in the following virtual investor conferences:

- **H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021:** Compass presentation will be broadcasted at 7:00 a.m. EST on March 9, 2021 and available on demand during the conference.
- **33rd Annual Roth Conference, March 15-17, 2021:** as part of a live panel on bispecific antibodies that will take place at 3:00 p.m. EDT on Tuesday, March 16, 2021.

A replay of Compass presentation will be available after the completion of the H.C. Wainwright Global Life Sciences Conference in the "Investors – Events and Presentations" tab on the Compass website [www.compasstherapeutics.com](http://www.compasstherapeutics.com).

### About Compass Therapeutics

Compass Therapeutics, Inc. (OTCQB: CMPX), is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The company's lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, and is currently being evaluated in a Phase 1b study. The Company's offices and labs are located in Boston, MA. Its website is at [www.compasstherapeutics.com](http://www.compasstherapeutics.com).

### Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to our product candidates and the development and therapeutic potential thereof, our technologies for identifying additional product candidates, and our business and development plans. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, our ability to identify additional product candidates for development, our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, and competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at [www.sec.gov](http://www.sec.gov), including without limitation our Form 10-Q for the quarter ended September 30, 2020, and our subsequent filings with the SEC.



### Investor Contact

Vered Bisker-Leib, President & Chief Operating Officer  
[ir@compasstherapeutics.com](mailto:ir@compasstherapeutics.com)

### Media Contact

[media@compasstherapeutics.com](mailto:media@compasstherapeutics.com)  
617-500-8099

Source: Compass Therapeutics, Inc.